Tyloxapol
Code | Size | Price |
---|
TAR-T0307-200mg | 200mg | £95.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0307-500mg | 500mg | £107.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0307-1g | 1g | £113.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Tyloxapol is a non-ionic liquid polymer used as a surfactant.
CAS:
25301-02-4
Formula:
C70H124O13
Molecular Weight:
137.18
Pathway:
GPCR/G Protein; NF-κb
Purity:
N/A
SMILES:
NCCC1=CC=C(O)C=C1
Target:
NF-κB; LPL Receptor
References
1. Rasouli M, et al. J Clin Diagn Res. 2016, 10(6):BF01-5.
2. Zheng J, et al. Chem Pharm Bull (Tokyo). 2010, 58(12):1612-1616.
3. Kristl J, et al. Toxicol Appl Pharmacol. 2008, 232(2):218-225.
4. Guo, Wen, et al. Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-?B and MAPK activation. Journal of Orthopaedic Translation . 28 (2021): 148-158.